

****Must Attach Demographic Face Sheet****

PATIENT INFORMATION

Patient Name: _____ DOB: _____

Phone Number: _____ E-mail: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ NPI: _____

Address: _____ Address 2: _____

City: _____ State: _____ Zip Code: _____

Office Contact: _____ Email: _____

Phone Number: _____ Fax Number: _____

PRESCRIPTION INFORMATION: NERIVIO RX

Quantity: 1 **Refills** ☐ 12 ☐ Other _____

Directions: Set a strong, yet comfortable intensity level for each 45 min treatment

- ☐ Acute: 45 min treatment at onset of migraine
- ☐ Prevention: 45 min treatment every other day, or as directed
- ☐ Dual Use: 45 min treatment every other day for prevention or at onset of migraine

Clinical Criteria - Check all that apply:

- ☐ Patients at risk of drug-drug interaction with other medications they are on
- ☐ Pregnant women, women that are trying to get pregnant, or women that are breast-feeding
- ☐ Tried and failed acute migraine medications (check all that apply):
- ☐ Triptans ☐ NSAIDs/oral analgesics ☐ Gepants
- ☐ Ditan ☐ Ergots ☐ Other: _____
- ☐ Tried and failed preventive migraine medications (check all that apply):
- ☐ Antiepileptic ☐ Beta Blockers ☐ Antidepressants
- ☐ Botox ☐ Monoclonal Antibodies
- ☐ Gepants ☐ Other: _____

Check the appropriate ICD-10 code:

- ☐ G43.001
- ☐ G43.009
- ☐ G43.011
- ☐ G43.019
- ☐ G43.101
- ☐ G43.109
- ☐ G43.111
- ☐ G43.119
- ☐ G43.701
- ☐ G43.709
- ☐ G43.711
- ☐ G43.719
- ☐ Other: G43. _____

Prescriber Signature: _____ Date: _____

METHODS OF PATIENT ENROLLMENT FOR NERIVIO:

Fax: 855-818-3781 | Phone: 877-210-1206 | Email: neriviorx@procarerx.com

E-prescribe to ProMod Rx (Miramar, FL)

NCPDP: 5742627 NPI: 1396394805

Nerivio
by theranica

Complete
Migraine Care

One Device for Effective Migraine Prevention and Treatment

Nerivio is a wearable migraine therapy that is safe and effective for preventing and treating migraine in patients ages 8 years and up.

Preventing Migraine¹

4
LESS

Monthly
Migraine
Days




Over half
of patients
had a

≥50%
reduction

in moderate
to severe
headache days.

Acute Treatment of Migraine²

Adults at 2-hours Post Treatment



Clinical trials demonstrate that Nerivio provides consistent relief of pain and associated migraine symptoms, as well as significant reduction in monthly migraine days

Effective • Drug Free • Discreet • Wearable

Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse.

Nerivio
by theranica

57%

of Adult Chronic patients achieved relief 2-hours post treatment with Nerivio.^{3,4}


72%

of children⁵ and adolescents⁶ achieved pain relief 2-hours post treatment with Nerivio.

Pivotal Acute RCT* in Adult Episodic Patients²

(* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=252)




After only one month, patients using Nerivio every other day showed a significant reduction in the number of migraine days per month.¹

Pivotal Prevention RTC*

(* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=248)



Significant reduction of MMD was reported in patients whether or not they were taking other preventive treatment in addition to Nerivio vs. placebo ($p \leq 0.03$).

Of the 128 Nerivio patients studied, zero patients reported device related adverse events in the pivotal prevention trial.¹

Scan here for clinical study info



1. Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023 Mar;63(3):377-389. doi: 10.1111/head.14469.
2. Yarnitsky D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551.
3. Nierenburg H, et al. Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study. Pain Ther. 2020 Dec;9(2):531-543. doi: 10.1007/s40122-020-00185-1.
4. Grosberg B, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep. 2021 Oct 14;6(4):e966. doi: 10.1097/PR9.0000000000000966.
5. Werner K, et al. Acute treatment of migraine in children aged 6–11: Real-world analysis of remote electrical neuromodulation (REN). Annals of the Child Neurology Society. 2024 June;2(2): 135-145. doi.org/10.1002/cns3.20073.
6. Hershey AD, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache. 2021 Feb;61(2):310-317. doi.org/10.1111/head.14042.

Scan here for important safety info

